RCS - Verici Dx PLC - Completion of ISO 27001 surveillance audit

Verici DxAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251103:nRSC7583Fa&default-theme=true

RNS Number : 7583F  Verici Dx PLC  03 November 2025

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Successful completion of ISO 27001 surveillance audit

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that it has successfully completed the annual
surveillance audit for its ISO 27001:2022 certification.

 

ISO 27001 is a globally recognised standard specifying data privacy and
security requirements for an Information Security Management System ("ISMS").
The annual surveillance audit aims to confirm that the Company is following
the highest level of standards enforced by the certification.

 

The Company's successful completion of this audit, along with its continued
commitment to protecting sensitive data and information, reinforces its
position as a trusted partner in the industry and in patient care. Continued
conformity with this standard means that Verici Dx's system meets world-wide
best practice with regards to managing risks related to the security of data
owned or handled by the Company.

 

Dave Schultenover, VP Quality and Regulatory Affairs at Verici Dx, said: "We
take our commitment to compliance at Verici Dx very seriously and pride
ourselves on performing with integrity that meets or exceeds industry
regulations and standards. We are pleased maintain this strong track record to
remain a trusted partner with our stakeholders and within the industry."

 

 Verici Dx plc                                 www.vericidx.com (https://vericidx.com/)

 Sara Barrington, CEO                          Via Walbrook PR

 Singer Capital Markets (Nominated adviser, Joint Broker)                     Tel: +44 (0)20 7496 3000
 Phil Davies / Sam Butcher

 Oberon Capital (Joint Broker)                 Tel: +44 (0)20 3179 0500
 Mike Seabrook / Adam Pollock

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
 Alice Woodings / Paul McManus                 Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEFLFXEBLXFBV



            Copyright 2019 Regulatory News Service, all rights reserved